Every year, during the Annual Meeting of the American Society of Hematology, the Ham-Wasserman Lecture is presented. This lectureship was named in honor of two past ASH presidents, the late Dr Thomas Hale Ham and the late Dr Louis R Wasserman. The Ham-Wasserman lecture is traditionally given by an individual from outside the United States who has made a major contribution to our understanding of an area that relates to hematology.

This year Dr Jesus San Miguel was selected for his major contribution in the field of Multiple Myeloma. He will present the Ham-Wasserman Lecture entitled “Multiple Myeloma: A Modern Model for Scientific and Clinical Progress”.

The European Hematology Association (EHA) congratulates 20 promising young researchers recently selected for the Translational Research Training in Hematology 2015 program. EHA and the American Society of Hematology (ASH) are proud to offer them a rigorous yearlong training, mentoring, and networking program in translational hematological research. TRTH faculty is made up of international leaders in hematology who cover biostatistics and biomarkers, genetics and molecular biology, ethics, and phase I clinical study design. The faculty of the program looks forward to working with the selected trainees on their research proposals, and to build collaborative networks for the future. 

 On July 22, the European Commission announced an update of the Work Programme 2014-2015. Hematologists should be aware that in 2015 opportunities are available to them in the Societal Challenge Health, demographic change and wellbeing.

Today, EU Reporter published an article by Ulrich Jäger, past president of the European Hematology Association (EHA) and chair of the European Affairs Committee, highlighting the importance of education and collaboration for the treatment of patients. 

Milan, June 13, 2014 - On Behalf of the RESONATE Investigators, Dr Hillmen will present the results from the Phase III trial in CLL and SLL patients.

Milan, June 13, 2014 – Promising results from phase-I study for CLL patients will be presented by Dr John Seymour.

Milan, June 13, 2014 – Dr Zafer Başlar will present the results of a multicenter study that was conducted in Turkey to evaluate the efficacy and tolerability of generics for CML patients.

Milan, June 13, 2014 – Dr Nicola Gökbuget will explain also on behalf of Max Topp, the results of two abstracts that will be presented during the 19th Congress of EHA about the treatment of ALL.

Milan, June 13, 2014 – New possible treatment options for thalassemia patients will be presented by Dr Olivier Hermine at the 19th Congress of EHA.

Milan, June 13, 2014 – Results from a large international study on pediatric ITP will be presented at the 19th Congress of EHA by Dr John Grainger.

Milan, June 13, 2014 – Dr Alessandro Vannucchi will present the promising results of a Phase III trial for polycythemia vera patients.

Multiple myeloma (MM), a proliferation (growth) of malignant plasma cells in the bone marrow destroying bones, accounts for 10% of all hematologic malignancies. Approximately 45.000 new cases are diagnosed each year together in the US and Europe. MM is mainly a disease of elderly people with age at diagnosis between 65-70 years.

The dramatic improvement in outcome for children with acute lymphoblastic leukemia is one of the major achievements in hematology in the last 40 years. However, while 90% of children with this disease can now be cured, the outlook has not been so good for the less common type of childhood leukemia, acute myeloid leukemia (AML). Although only 1 in 7 children with leukemia have AML, half of these children will die from their disease. The challenge now is to harness the new developments in genomics to improve the outcome for these children.

Blood cancers (leukemias) are life-threatening diseases that can devastate the lives of patients and their families. Great progress has been made in treatments to improve the survival of these otherwise invariably fatal conditions. Major advances in the understanding of leukemia genetics for genome sequencing of individual patients has taken us one step further towards realizing personalized medicine for many patients.

The International Society on Thrombosis and Haemostasis (ISTH) partners with thrombosis related organizations from every continent to launch World Thrombosis Day focused on single cause of top 3 cardiovascular deaths worldwide.

EHA endorses and supports the initiative for this World Thromobis Day.